Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 11, 2010, Pages 1657-1669

  Bozhanov, Stefan S ^a   Angelova, Svetla G ^a   Krasteva, Maria E ^a   Markov, Tsanko L ^a   Christova, Svetlana L ^b   Gavrilov, Ivan G ^c   Georgieva, Elena I ^a  

^a INSTITUTE OF PHYSIOLOGY   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c National Oncology Center Bulgaria   (Bulgaria)

Author keywords

Breast cancer; Clinicopathological characteristics; Mutations; Overall survival; Proto oncogenes; Tumor suppressor genes

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PROTEIN P53; UNCLASSIFIED DRUG; ATM PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROGESTERONE RECEPTOR; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BULGARIA; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTO ONCOGENE; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BREAST TUMOR; EXON; GENETICS; INTRON; ISOLATION AND PURIFICATION; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRCA1 PROTEIN; BREAST NEOPLASMS; BULGARIA; CELL CYCLE PROTEINS; DNA, NEOPLASM; DNA-BINDING PROTEINS; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; GENES, P53; HUMANS; INTRONS; LYMPHATIC METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVORS; TUMOR SUPPRESSOR PROTEINS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77957603427     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0824-9     Document Type: Article

References (54)

1. KE Bachman P Argani Y Samuels N Silliman J Ptak S Szabo H Konishi B Karakas BG Blair C Lin BA Peters VE Velculescu BH Park 2004 The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol Ther 3 772 775 1:CAS:528:DC%2BD2MXhslKrtbw%3D 10.4161/cbt.3.8.994 15254419 (Pubitemid 41351083)
2. AG Bader S Kang PK Vogt 2006 Cancer-specific mutations in PIK3CA are oncogenic in vivo Proc Natl Acad Sci USA 103 1475 1479 10.1073/pnas.0510857103 1:CAS:528:DC%2BD28Xhs1Gns7g%3D 10.1073/pnas.0510857103 16432179 (Pubitemid 43191190)
3. M Barbareschi F Buttitta L Felicioni S Cotrupi F Barassi M Del Grammastro A Ferro P Dalla Palma E Galligioni A Marchetti 2007 Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas Clin Cancer Res 13 6064 6069 10.1158/1078-0432.CCR-07-0266 1:CAS:528:DC%2BD2sXhtFygs7nL 10.1158/1078-0432.CCR-07-0266 17947469 (Pubitemid 350075063)
4. J Bartkova Z Horvejsv K Koed A Kramer F Tort K Zieger P Guldberg M Sehested MJ Nesland C Lukas T Orntoft J Lukas J Bartek 2005 DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 864 870 1:CAS:528:DC%2BD2MXjtFOms7k%3D 10.1038/nature03482 15829956 (Pubitemid 40558993)
5. AL Borresen-Dale 2003 TP53 and breast cancer Hum Mutat 21 292 300 10.1002/humu.10174 1:CAS:528:DC%2BD3sXis1yjtLw%3D 10.1002/humu.10174 12619115 (Pubitemid 36292971)
6. SB Bull H Ozcelik D Pinnaduwage ME Blackstein DA Sutherland KI Pritchard AT Tzontcheva S Sidlofsky WM Hanna AH Qizilbash ME Tweeddale S Fine DR McCready IL Andrulis 2004 The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer J Clin Oncol 22 86 96 10.1200/JCO.2004.09.128 1:CAS:528:DC%2BD2cXpsVKiurc%3D 10.1200/JCO.2004.09. 128 14701769 (Pubitemid 41095118)
7. CH Buzin SH Tang JM Cunningham A Shibata RK Ross A Hartmann H Blaszyk JS Kovach 2001 Low frequency of p53 gene mutations in breast cancers of Japanese-American women Nutr Cancer 39 72 77 1:CAS:528:DC%2BD3MXnsVCnur0%3D 10.1207/S15327914nc391-10 11588905
8. IG Campbell SE Russell DY Choong KG Montgomery ML Ciavarella CS Hooi BE Cristiano RB Pearson WA Phillips 2004 Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 7678 7681 1:CAS:528:DC%2BD2cXptFemtbk%3D 10.1158/0008-5472.CAN-04-2933 15520168 (Pubitemid 39446895)
9. JA Carr S Havstad RJ Zarbo G Divine P Mackowiak V Velanovich 2000 The association of HER-2/neu amplification with breast cancer recurrence Arch Surg 135 1469 1474 1:STN:280:DC%2BD3M7htVemsQ%3D%3D 10.1001/archsurg.135.12.1469 11115354
10. Danon Sh, Valerianova Zdr, Ivanova Tzv (2006) Bulgarian National Cancer Registry. Cancer incidence in Bulgaria 2003. Bulgarian Publishing House, Sofia
11. T Dork R Bendix M Bremer D Rades K Klopper M Nicke B Skawran A Hector P Yamini D Steinmann S Weise M Stuhrmann JH Karstens 2001 Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients Cancer Res 61 7608 7615 1:CAS:528:DC%2BD3MXnvFShtro%3D 11606401
12. DF Easton 1994 Cancer risks in A-T heterozygotes Int J Radiat Biol 66 177 182 10.1080/09553009414552011
13. RM Elledge SAW Fuqua GM Clark P Pujol DC Allred WL Mcguire 1993 Prognostic significance of p53 gene alterations in nodenegative breast cancer Breast Cancer Res Treat 26 225 235 1:STN:280:DyaK2c%2Fnt1OnsQ%3D%3D 10.1007/BF00665800 8251647 (Pubitemid 23304238)
14. M Esteller JM Silva G Dominguez F Bonilla X Matias-Guiu E Lerma E Bussaglia J Prat IC Harkes EA Repasky E Gabrielson M Schutte SB Baylin JG Herman 2000 Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 Suppl 7 564 569 1:CAS:528: DC%2BD3cXivFWqtr8%3D 10.1093/jnci/92.7.564 10749912
15. D Ford DF Easton M Stratton S Narod D Goldgar P Devilee DT Bishop B Weber G Lenoir J Chang-Claude H Sobol MD Teare J Struewing A Arason S Scherneck J Peto TR Rebbeck P Tonin S Neuhausen R Barkardottir J Eyfjord H Lynch BAJ Ponder SA Gayther JM Birch A Lindblom D Stoppa-Lyonnet Y Bignon A Borg U Hamann, et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families Am J Hum Genet 62 676 689 1:CAS:528:DyaK1MXlvFeh 10.1086/301749 9497246 (Pubitemid 28164626)
16. LS Friedman EA Ostermeyer CI Szabo P Dowd ED Lynch SE Rowell MC King 1994 Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families Nat Genet 8 399 404 1:CAS:528:DyaK2MXitl2hsb0%3D 10.1038/ng1294-399 7894493 (Pubitemid 24375608)
17. RA Gatti A Tward P Concannon 1999 Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations Mol Genet Metab 68 419 423 10.1006/mgme.1999.2942 1:CAS:528: DyaK1MXotVGgs7o%3D 10.1006/mgme.1999.2942 10607471 (Pubitemid 30043548)
18. M Georgieva M Krasteva E Angelova K Ralchev V Dimitrov S Bozhimirov E Georgieva MR Berger 2008 Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients Oncol Rep 20 Suppl 1 3 11 1:CAS:528:DC%2BD1cXptFent7w%3D 18575712
19. P González-Hormazábal T Bravo R Blanco YC Valenzuela F Gómez E Waugh O Peralta W Ortuzar JM Reyes L Jara 2008 Association of common ATM variants with familial breast cancer in a South American population BMC Cancer 8 117 10.1186/1471-2407-8-117 10.1186/1471-2407-8-117 18433505 (Pubitemid 351712546)
20. K Heikkinen K Rapakko SM Karppinen H Erkko P Nieminen R Winqvist 2005 Association of common ATM polymorphism with bilateral breast cancer Int J Cancer 116 69 72 10.1002/ijc.20996 1:CAS:528:DC%2BD2MXls1KjtrY%3D 10.1002/ijc.20996 15756685 (Pubitemid 40827756)
21. T Ikenoue F Kanai Y Hikiba T Obata Y Tanaka J Imamura M Ohta A Jazag B Guleng K Tateishi Y Asaoka M Matsumura T Kawabe M Omata 2005 Functional analysis of PIK3CA gene mutations in human colorectal cancer Cancer Res 65 4562 4567 1:CAS:528:DC%2BD2MXks1Oht7c%3D 10.1158/0008-5472.CAN-04-4114 15930273 (Pubitemid 40740791)
22. L Izatt J Greenman S Hodgson D Ellis S Watts G Scott C Jacobs R Liebmann MJ Zvelebil C Mathew E Solomon 2000 Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer Genes Chromosomes Cancer 26 286 294 10.1002/(SICI)1098-2264(199912)26:4<286: :AID-GCC2>3.0.CO;2-X
23. KK Khanna G Chenevix-Trench 2004 ATM and genome maintenance: defining its role in breast cancer susceptibility J Mammary Gland Biol Neoplasia 9 247 262 10.1023/B:JOMG.0000048772.92326.a1 10.1023/B:JOMG.0000048772.92326.a1 15557798 (Pubitemid 39545742)
24. KK Khanna MF Lavin SP Jackson TD Mulhern 2001 ATM, a central controller of cellular responses to DNA damage Cell Death Differ 8 1052 1065 1:CAS:528:DC%2BD3MXoslWjsb8%3D 10.1038/sj.cdd.4400874 11687884 (Pubitemid 33061823)
25. ME Krasteva EI Georgieva 2006 Germline p53 single-base changes associated with Balkan endemic nephropathy Biochem Biophys Res Commun 342 562 567 10.1016/j.bbrc.2006.02.004 1:CAS:528:DC%2BD28XhvVehs7c%3D 10.1016/j.bbrc.2006. 02.004 16487937 (Pubitemid 43292339)
26. ME Krasteva Z Garanina EI Georgieva 2003 Optimized polymerase chain reaction-based single-strand conformation polymorphism analysis of p53 gene applied to Bulgarian patients with invasive breast cancer Clin Exp Med 3 173 180 10.1007/s10238-003-0022-z 1:CAS:528:DC%2BD3sXpt1ChtLw%3D 10.1007/s10238-003- 0022-z 14648233 (Pubitemid 37491548)
27. M Lacroix RA Toillon G Leclercq 2006 p53 and breast cancer, an update Endocr Relat Cancer 13 293 325 10.1677/erc.1.01172 1:CAS:528: DC%2BD28XntF2mtL4%3D 10.1677/erc.1.01172 16728565 (Pubitemid 43886660)
28. A Langerød H Zhao ∅ Borgan JM Nesland IR Bukholm T Ikdahl R Kåresen AL Børresen-Dale SS Jeffrey 2007 TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer Breast Cancer Res 9 Suppl 3 30 10.1186/bcr1675 10.1186/bcr1675 (Pubitemid 350215177)
29. SY Li M Rong F Grieu B Iacopetta 2006 PIK3CA mutations in breast cancer are associated with poor outcome Breast Cancer Res Treat 96 91 95 10.1007/s10549-005-9048-0 1:CAS:528:DC%2BD28XivVensbk%3D 10.1007/s10549-005- 9048-0 16317585
30. C Liedtke L Cardone A Tordai K Yan HL Gomez LB Figureoa RE Hubbard V Valero EA Souchon WF Symmans GN Hortobagyi A Bardelli L Pusztai 2008 PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer Breast Cancer Res 10 Suppl 2 27 10.1186/bcr1984 10.1186/bcr1984
31. P Maillet PO Chappuis G Vaudan Z Dobbie H Muller P Hutter AP Sappino 2000 A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer Int J Cancer 88 928 931 10.1002/1097- 0215(20001215)88:6<928::AID-IJC14>3.0.CO;2-P 1:CAS:528: DC%2BD3cXovVGhtLs%3D 10.1002/1097-0215(20001215)88:6<928::AID-IJC14>3.0. CO;2-P 11093816
32. A Markoff H Sormbroen N Bogdanova S Preisler-Adams V Ganev B Dworniczak J Horst 1998 Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols Eur J Hum Genet 6 145 150 1:CAS:528:DyaK1MXhsFGktbo%3D 10.1038/sj.ejhg.5200171 9781059
33. N Maruyama Y Miyoshi T Taguchi Y Tamaki M Monden S Noguchi 2007 Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 15 408 414 10.1158/1078-0432.CCR-06-0267 (Pubitemid 46225343)
34. M Olivier A Langerod P Carrieri J Bergh S Klaar J Eyfjord C Theillet C Rodriguez R Lidereau I Bieche J Varley Y Bignon N Uhrhammer R Winqvist A Jukkola-Vuorinen D Niederacher S Kato C Ishioka P Hainaut AL Borresen-Dale 2006 The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer Clin Cancer Res 12 1157 1167 10.1158/1078-0432.CCR-05-1029 1:CAS:528:DC%2BD28XhsFalt7Y%3D 10.1158/1078-0432.CCR-05-1029 16489069 (Pubitemid 43342504)
35. A Petitjean MI Achatz AL Borresen-Dale P Hainaut M Olivier 2007 TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 26 2157 2165 10.1038/sj.onc.1210302 1:CAS:528: DC%2BD2sXjs1yqtL4%3D 10.1038/sj.onc.1210302 17401424 (Pubitemid 46536647)
36. E Rahko G Blanco Y Soini R Bloigu A Jukkola 2003 A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients Eur J Cancer 39 447 453 1:CAS:528:DC%2BD3sXhtVemurg%3D 10.1016/S0959-8049(02)00499-9 12751374 (Pubitemid 36173688)
37. PP Rosen ML Lesser CD Arroyo M Cranor P Borgen L Norton 1995 p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis J Clin Oncol 13 821 830 1:STN:280:DyaK2M3it1ejtQ%3D%3D 7707107
38. JS Ross JA Fletcher GP Linette J Stec E Clark M Ayers WF Symmans L Pusztai KJ Bloom 2003 The Her-2/neu gene and protein in breast cancer: biomarker and target of therapy Oncologist 8 307 325 1:CAS:528:DC%2BD3sXmvFSqt74%3D 10.1634/theoncologist.8-4-307 12897328 (Pubitemid 36929717)
39. P Rudolph H Olsson G Bonatz V Ratjen H Bolte B Baldetorp M Fernö R Parwaresch P Alm 1999 Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications J Pathol 187 207 216 10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U 1:CAS:528:DyaK1MXht1Cnu7w%3D 10.1002/(SICI)1096-9896(199901)187:2<207::AID- PATH223>3.0.CO;2-U 10365096 (Pubitemid 29037050)
40. LH Saal K Holm M Maurer L Memeo T Su X Wang JS Yu PO Malmstrom M Mansukhani J Enoksson H Hibshoosh A Borg R Parsons 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 2554 2559 1:CAS:528:DC%2BD2MXjtVeqsrc%3D 10.1158/0008-5472-CAN-04-3913 15805248 (Pubitemid 40490050)
41. Y Samuels Z Wang A Bardelli N Silliman J Ptak S Szabo H Yan A Gazdar SM Powell GJ Riggins JK Willson S Markowitz KW Kinzler B Vogelstein VE Velculescu 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 554 10.1126/science.1096502 1:CAS:528:DC%2BD2cXjsVGmsbk%3D 10.1126/science. 1096502 15016963 (Pubitemid 38541907)
42. Y Samuels LA Diaz Jr O Schmidt-Kittler JM Cummins L Delong I Cheong C Rago DL Huso C Lengauer KW Kinzler B Vogelstein VE Velculescu 2005 Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 561 573 1:CAS:528:DC%2BD2MXlslCgsrY%3D 10.1016/j.ccr.2005.05.014 15950905 (Pubitemid 40799249)
43. I Sansal WR Sellers 2004 The biology, clinical relevance of the PTEN tumor suppressor pathway J Clin Oncol 22 2954 2963 10.1200/JCO.2004.02.141 1:CAS:528:DC%2BD2cXpsVWktbk%3D 10.1200/JCO.2004.02.141 15254063 (Pubitemid 41079915)
44. M Sawaki Y Ito F Akiyama N Tokudome R Horii N Mizunuma S Takahashi N Horikoshi T Imai A Nakao F Kasumi G Sakamoto K Hatake 2006 High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer Breast Cancer 13 172 178 10.2325/jbcs.13.172 10.2325/jbcs.13.172 16755113
45. B Singh PG Reddy A Goberdhan C Walsh S Dao I Ngai TC Chou P O-charoenrat AJ Levine PH Rao A Stoffel 2002 p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas Genes Dev 16 984 993 10.1101/gad.973602 1:CAS:528:DC%2BD38Xjt1GktbY%3D 10.1101/gad.973602 11959846 (Pubitemid 34408547)
46. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
47. M Swift D Morrell RB Massey CL Chase 1991 Incidence of cancer in 161 families affected by ataxiatelangiectasia N Engl J Med 325 1831 1836 1:STN:280:DyaK38%2Fnt1KgsA%3D%3D 10.1056/NEJM199112263252602 1961222
48. D Thompson S Duedal J Kirner L McGuffog J Last A Reiman P Byrd M Taylor DF Easton 2005 Cancer risks and mortality in heterozygous ATM mutation carriers J Natl Cancer Inst 97 813 822 10.1093/jnci/dji141 1:CAS:528:DC%2BD2MXkvVShtbc%3D 10.1093/jnci/dji141 15928302 (Pubitemid 40909124)
49. J Tommiska L Jansen O Kilpivaara H Edvardsen V Kristensen A Tamminen K Aittomaki C Blomqvist AL Borresen-Dale H Nevanlinna 2006 ATM variants and cancer risk in breast cancer patients from Southern Finland BMC Cancer 6 209 10.1186/1471-2407-6-209 10.1186/1471-2407-6-209 16914028 (Pubitemid 44530032)
50. RS Tuma 2005 Trastuzumab trials steal show at ASCO meeting J Natl Cancer Inst 97 870 871 10.1093/jnci/97.12.870 10.1093/jnci/97.12.870 15956644
51. PK Vogt S Kang MA Elsliger M Gymnopoulos 2007 Cancer-specific mutations in phosphatidylinositol 3-kinase Trends Biochem Sci 32 342 349 10.1016/j.tibs.2007.05.005 1:CAS:528:DC%2BD2sXnsFKlurc%3D 10.1016/j.tibs.2007. 05.005 17561399 (Pubitemid 47021415)
52. DB Whyte SL Holbeck 2006 Correlation of PIK3CA mutations with gene expression and drug sensitivity in NCI-60 cell lines Biochem Biophys Res Commun 340 469 475 10.1016/j.bbrc.2005.12.025 1:CAS:528:DC%2BD28XhvFKguw%3D%3D 10.1016/j.bbrc.2005.12.025 16376301 (Pubitemid 43021772)
53. H Yamashita M Nishio T Toyama H Sugiura Z Zhang S Kobayashi H Iwase 2004 Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer Breast Cancer Res 6 Suppl 1 24 30 10.1186/bcr738 10.1186/bcr738
54. H Yamashita M Nishio S Kobayashi A Ando H Sugiura Z Zhang M Hamaguchi K Mita Y Fujii H Iwase 2005 Phosphorylation of estrogen receptor a serine167 is predictive of response to endocrine therapy and increases post relapse survival in metastatic breast cancer Breast Cancer Res 7 753 764 10.1186/bcr1536 10.1186/bcr1285